194 related articles for article (PubMed ID: 32113839)
1. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Dong C; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Semin Arthritis Rheum; 2020 Dec; 50(6):1513-1520. PubMed ID: 32113839
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study.
Chen Y; Li R; Luo X; Wu T; Li J; Liu Z; Peng Y; Lu H; Peng L; Zhou J; Zhao Y; Zeng X; Fei Y; Zhang W
Clin Rheumatol; 2023 Jul; 42(7):1839-1846. PubMed ID: 36781683
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Omar D; Chen Y; Cong Y; Dong L
Rheumatology (Oxford); 2020 Apr; 59(4):718-726. PubMed ID: 31511884
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease.
Wang Y; Zhao Z; Gao D; Wang H; Liao S; Luo G; Ji X; Li Y; Wang X; Zhao Y; Li K; Zhang J; Jin J; Zhang Y; Zhu J; Zhang J; Huang F
Clin Rheumatol; 2023 Jan; 42(1):135-143. PubMed ID: 36074221
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids in the treatment of IgG4-related disease-Prospects for new international treatment guidelines.
Yoshifuji H; Umehara H
Mod Rheumatol; 2023 Mar; 33(2):252-257. PubMed ID: 35993488
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study.
Luo X; Peng Y; Zhang P; Li J; Liu Z; Lu H; Zhang X; Zeng X; Zhang F; Fei Y; Zhang W
Front Med (Lausanne); 2020; 7():253. PubMed ID: 32733900
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial.
Yunyun F; Yu P; Panpan Z; Xia Z; Linyi P; Jiaxin Z; Li Z; Shangzhu Z; Jinjing L; Di W; Yamin L; Xiaowei L; Huadan X; Xuan Z; Xiaofeng Z; Fengchun Z; Yan Z; Wen Z
Rheumatology (Oxford); 2019 Jan; 58(1):52-60. PubMed ID: 30124952
[TBL] [Abstract][Full Text] [Related]
9. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients.
Wang L; Zhang P; Wang M; Feng R; Lai Y; Peng L; Fei Y; Zhang X; Zhao Y; Zeng X; Zhang F; Zhang W
Arthritis Res Ther; 2018 Apr; 20(1):65. PubMed ID: 29636109
[TBL] [Abstract][Full Text] [Related]
10. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
11. Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Liu Y; Zeng Q; Zhu L; Gao J; Wang Z; Wang Z; Yang F; Wang K; Chen D; Xia C; Zhang S; Wang Y; Shen D; Yu G; Li ZG
Rheumatology (Oxford); 2020 Aug; 59(8):2115-2123. PubMed ID: 32097488
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study.
Peng Y; Li JQ; Zhang PP; Zhang X; Peng LY; Chen H; Zhou JX; Zhang SZ; Yang HX; Liu JJ; Guo HF; Li J; Zhang X; Zhao Y; Zeng XF; Zhang FC; Fei YY; Zhang W
J Intern Med; 2019 Nov; 286(5):542-552. PubMed ID: 31121062
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Liu Y; Zhang Y; Bian W; Fu J; Sun X; Chen D; Chen J; Zhao X; Li Y; Zhang W; Li Z
Clin Rheumatol; 2020 Feb; 39(2):491-497. PubMed ID: 31848912
[TBL] [Abstract][Full Text] [Related]
14. Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents.
Hong X; Zhang YY; Li W; Liu YY; Wang Z; Chen Y; Gao Y; Sun ZP; Peng X; Su JZ; Cai ZG; Zhang L; He J; Ren LM; Yang HY; Li ZG; Yu GY
Arthritis Res Ther; 2018 Jan; 20(1):12. PubMed ID: 29382364
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and relapse risks factors of IgG4 related disease: a single-center retrospective study.
Zhang X; Zeng Z; Tian H; Wang N; Wang Y; Tong J; Chang B; Jin X; Huang D; Wang Y; Cui H; Guan L; Li Y
Clin Exp Med; 2023 Nov; 23(7):3527-3538. PubMed ID: 37392248
[TBL] [Abstract][Full Text] [Related]
16. Does leflunomide have a role in giant cell arteritis? An open-label study.
Hočevar A; Ješe R; Rotar Ž; Tomšič M
Clin Rheumatol; 2019 Feb; 38(2):291-296. PubMed ID: 30084049
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study.
Wang J; Dai X; Ma L; Wu S; Jin X; Ji Z; Chen H; Ma L; Ding Z; Jiang L; Kong X
Semin Arthritis Rheum; 2022 Aug; 55():152018. PubMed ID: 35523066
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.
An W; Wu Z; Li M; Yu H; Zhao X; Wang X; Wang Y; Wang Q; Duan W; Kong Y; Ma H; Ou X; You H; Liu Y; Li P; Duan T; Jia J
Orphanet J Rare Dis; 2022 Aug; 17(1):307. PubMed ID: 35927746
[TBL] [Abstract][Full Text] [Related]
19. Therapy of immunoglonuline IgG4 related disease (IgG4-RD).
Adam Z; Dastych M; Čermák A; Doubková M; Skorkovská Š; Pour L; Řehák Z; Koukalová R; Adamová Z; Štork M; Krejčí M; Boichuk I; Král Z
Vnitr Lek; 2022; 68(E-6):15-22. PubMed ID: 36316207
[TBL] [Abstract][Full Text] [Related]
20. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
